Finance

Lists
Why is ZBIO up 3.89%?
Dive Deeper
ZBIO:NASDAQ
Zenas Biopharma Inc
$ 27.26
+3.89%
(+1.02) 1D
$ 26.94
-1.17% (-0.32)
After hours
Closed: 10-р сарын 9, 16:00:00 (GMT-4)  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ZBIO...
Open
$ 26.18
High
$ 27.64
Low
$ 26.18
Mkt. cap
1.78 тэрбум
Avg. vol.
685.10 мян
Volume
429.82 мян
52-wk high
$ 44.54
52-wk low
$ 13.50
EPS
-$ 8.97
Shares outstanding
65.18 сая
No. of employees
167
Open
$ 26.18
High
$ 27.64
Low
$ 26.18
Mkt. cap
1.78 тэрбум
Avg. vol.
685.10 мян
Volume
429.82 мян
52-wk high
$ 44.54
52-wk low
$ 13.50
EPS
-$ 8.97
Shares outstanding
65.18 сая
No. of employees
167
News stories
From web sources and news partners
About Zenas Biopharma Inc
CEO-
Employees167
Founded2019
HeadquartersWaltham, Массачусеттс, Америкийн Нэгдсэн Улс
Sector-
Analyst ratings
Based on 5 analysts giving stock ratings to ZBIO in the past 3 months
Strong buy
Buy
4
Hold
1
Sell
0
12-month forecast
Based on 5 Wall Street analysts offering 12 month price targets for ZBIO in the last 3 months.
Highest
Current $ 27.26
$ 55.00 (+101.76%)
Average
$ 44.80 (+64.34%)
Lowest
$ 32.00 (+17.39%)
Analyst
Recommendation
Action
Price target
Projected
Date
Yigal Nochomovitz
Citi
Buy
Maintained
$ 48.00
+76.1%
10/01/2026
Martin Fan
Wedbush
Buy
Maintained
$ 45.00
+65.1%
09/30/2026
Unknown Analyst
Wedbush
Buy
Maintained
$ 45.00
+65.1%
09/30/2026
Matthew Caufield
H.C. Wainwright
Buy
Reiterated
$ 44.00
+61.4%
09/30/2026
Judah Frommer
Morgan Stanley
Hold
Maintained
$ 32.00
+17.4%
08/17/2026
David Nierengarten
Wedbush
Buy
Maintained
$ 45.00
+65.1%
08/14/2026
Yatin Suneja
Guggenheim
Buy
Reiterated
$ 55.00
+101.8%
08/13/2026
Patrick Trucchio
H.C. Wainwright
Buy
Reiterated
$ 44.00
+61.4%
06/08/2026
Cory Kasimov
Evercore ISI
Buy
Maintained
$ 55.00
+101.8%
03/17/2026
Last report
2026 оны 8-р сарын 13
Fiscal period
Q2 2026
-$ 1.77 / -$ 0.75
-134.44%miss
Revenue / Est. (USD)
1.00 сая / 15.00 сая
-93.33%miss
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025 оны 9-р сар
2025 оны 12-р сар
2026 оны 3-р сар
2026 оны 6-р сар
Revenue
-
-
-
1.00 сая
Cost of goods sold
34.40 сая
55.72 сая
60.44 сая
62.91 сая
Cost of revenue
34.40 сая
55.72 сая
60.44 сая
62.91 сая
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
13.18 сая
15.59 сая
16.91 сая
15.75 сая
Operating expense
13.18 сая
15.59 сая
16.91 сая
15.75 сая
Total operating expenses
47.58 сая
71.31 сая
77.35 сая
78.66 сая
Operating income
-47.58 сая
-71.31 сая
-77.35 сая
-77.66 сая
Other non operating income
1.08 сая
-7.48 сая
-24.00 мян
16.00 мян
EBT including unusual items
-51.50 сая
-240.34 сая
-80.99 сая
-111.34 сая
EBT excluding unusual items
-46.50 сая
-73.66 сая
-80.99 сая
-81.34 сая
Income tax expense
-
106.00 мян
-
114.00 мян
Effective tax rate
-
-0.04%
-
-0.10%
Other operating expenses
-
-
-
-
Net income
-51.50 сая
-240.44 сая
-80.99 сая
-111.46 сая
Net profit margin
-
-
-
-11,145.60%
Earnings per share
-1.22
-1.39
-1.46
-1.77
Interest and investment income
-
12.15 сая
3.02 сая
6.60 сая
Interest expense
-
-7.33 сая
-6.63 сая
-10.30 сая
Net interest expenses
-
4.82 сая
-3.61 сая
-3.70 сая
Depreciation and amortization charges
-
-
-
-
EBITDA
-47.57 сая
-71.30 сая
-77.34 сая
-77.66 сая
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google аппс